A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study. Itsara A, Rogness VM, Samples L, Yuan CM, et al. Blood 2026;147:1702-1712.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Itsara A, Rogness VM, Samples L, Yuan CM, et al. A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study. Blood 2026;147:1702-1712.
PMID: 41405491